Our site uses cookies to offer you a better user experience. By continuing to use this site, you agree to our use of cookies. To find out more, read our Privacy and Cookies policies.
  • All Journals
  • Exploration of Medicine
  • Exploration of Targeted Anti-tumor Therapy
  • Exploration of Immunology
  • Exploration of Neuroprotective Therapy
  • Exploration of Digestive Diseases
  • Exploration of Neuroscience
  • Exploration of Musculoskeletal Diseases
  • Exploration of Drug Science
  • Exploration of Asthma & Allergy
  • Exploration of Foods and Foodomics
  • Exploration of Digital Health Technologies
  • Exploration of Cardiology
  • Exploration of BioMat-X
  • Exploration of Endocrine and Metabolic Diseases
  • All
  • Article Title
  • Abstract
  • Keywords
  • Author
  • Institution
2514 results in Open Exploration
  • Relevance
  • Publication Date
Sort by :
Open Access Perspective
The intermicrovillar adhesion complex in gut barrier function and inflammation
Bernadette Mödl ... Robert Eferl
Published: October 11, 2022 Explor Dig Dis. 2022;1:72–79
6994 83 8
Open Access Review
Neuroprotective and neurorestorative actions of mesenchymal stromal cell-derived small extracellular vesicles in the ischemic brain
Chen Wang ... Dirk M. Hermann
Published: October 09, 2022 Explor Neurosci. 2022;1:61–74
6393 68 2
Open Access Perspective
Recent developments and future perspectives of neuropathology
Kurt A. Jellinger
Published: September 30, 2022 Explor Neurosci. 2022;1:54–60
6551 64 1
Open Access Original Article
N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas
Feng Yuan ... Chiyuan Ma
Published: September 30, 2022 Explor Target Antitumor Ther. 2022;3:553–569
This article belongs to the special issue Theranostic Frontiers in Neuro-Oncology
3999 45 2
Open Access Review
Impact of circadian clock dysfunction on human health
Saptadip Samanta, Sk Asif Ali
Published: September 29, 2022 Explor Neurosci. 2022;1:4–30
This article belongs to the special issue Circadian Rhythm and Melatonin
35875 357 17
Open Access Review
Neuregulins: subcellular localization, signaling pathways and their relationship with neuroplasticity and neurological diseases
Marines Longart ... Juan Carlos Martínez
Published: September 29, 2022 Explor Neurosci. 2022;1:31–53
9292 95 5
Open Access Review
Immune responses to SARS-CoV-2 infection and COVID-19 vaccines
Basista Rabina Sharma, P. Veeranna Ravindra
Published: September 21, 2022 Explor Immunol. 2022;2:648–664
This article belongs to the special issue Vaccine-induced Immune Responses Against SARS-CoV-2 Infections
6264 115 2
Open Access Editorial
Cutting edges in neuroscience to exceed borders
Dirk M. Hermann
Published: September 01, 2022 Explor Neurosci. 2022;1:1–3
3200 48 2
Open Access Review
miRNA therapeutics in precision oncology: a natural premium to nurture
Chakresh Kumar Jain ... R Suresh Kumar
Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:511–532
7195 52 5
Open Access Review
Clinical applications of liquid biopsy in HPV-negative and HPV-positive head and neck squamous cell carcinoma: advances and challenges
Mariana Chantre-Justino ... Lucas Delmonico
Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:533–552
7352 78 6
Open Access Review
Chemokines and nanomaterials: interaction for useful immune-applications
Giuseppe Bardi
Published: August 31, 2022 Explor Immunol. 2022;2:637–647
7718 332 4
Open Access Review
Paradoxical role of reactive oxygen species in bone remodelling: implications in osteoporosis and possible nanotherapeutic interventions
Largee Biswas ... Anita Kamra Verma
Published: August 31, 2022 Explor Med. 2022;3:393–413
This article belongs to the special issue Reactive Oxygen Species (ROS) in Pathophysiological Conditions
9338 131 22
Open Access Review
Roles of calcium signaling in cancer metastasis to bone
Tianying Xie ... Jianru Xiao
Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:445–462
This article belongs to the special issue Calcium Signaling Apparatus in Cancers
8043 79 12
Open Access Review
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors
Vincenzo Raimondi ... Nicola Giuliani
Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:463–479
This article belongs to the special issue Off-Label Drugs and -Omics Data in Cancer Treatment
6527 52 7
Open Access Review
Endocrine therapy resistance: what we know and future directions
David Musheyev, Anya Alayev
Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:480–496
This article belongs to the special issue Endocrine Resistant Breast Cancer
8885 68 16
Open Access Review
Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets
Mohammad A. Al-Mterin, Eyad Elkord
Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:497–510
This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
8506 77 14
Open Access Review
Vaccine induced thrombotic thrombocytopenia: development and reactivity of anti-platelet factor 4 antibodies and immune pathogenic mechanisms
Jean Amiral ... Gwenaëlle Renaud
Published: August 31, 2022 Explor Immunol. 2022;2:604–621
5606 37 3
Open Access Review
A non-redundant role of complement protein C1q in normal and adverse pregnancy
Chiara Agostinis ... Roberta Bulla
Published: August 31, 2022 Explor Immunol. 2022;2:622–636
This article belongs to the special issue Human Reproduction: Involvement of the Immune System
8379 88 8
Open Access Case Report
A case report: 19-year-old male diagnosed with C1q nephropathy requiring renal replacement therapy
Randa Choueiri ... Vanessa Nseir
Published: August 31, 2022 Explor Med. 2022;3:386–392
8646 86 2
Open Access Review
Applications and challenges of biomaterial mediated mRNA delivery
Huapan Fang, Qian Chen
Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:428–444
This article belongs to the special issue Gene Delivery Approach to Fight Cancer
7737 52 10